Previous studies reported that the risk of early relapse is greater for women with estrogen receptor (ER)-negative than ER-positive breast cancer, but late relapses are more common in ER-positive than ER-negative disease [4]–[6]. This evidence concerns the gene ESR1 and breast cancer.